Natera, Inc.
Natera, Inc. develops molecular diagnostic tests for women's health (prenatal screening), organ health (transplant monitoring), and oncology (cancer recurrence)
Natera, Inc. develops molecular diagnostic tests for women's health (prenatal screening), organ health (transplant monitoring), and oncology (cancer recurrence). Signatera, its fastest-growing segment, recently gained FDA, Japanese PMDA, and EU approvals, and NCCN Category 1 recommendation. Natera also received FDA Breakthrough Device designation for its multi-cancer early detection assay. The company sells globally to healthcare providers and labs.
Not in registry
Source Essential for Natera's molecular diagnostics tests, including SNP-informed deep-sequencing and multiplex PCR NGS assays. Reagents are a major part of the 'consumables' category which dominates market share.
Confidence: high
Not in registry
Source General lab supplies needed for sample processing and test execution. Part of the broader 'consumables' category.
Confidence: high
Not in registry
Source Technician time is a direct cost component of running genetic tests in Natera's CLIA-certified labs in Austin, San Carlos, and Boulder.
Confidence: high
Not in registry
Source Sequencing machines are complex, expensive instruments with a limit to the number of samples that can be run simultaneously, contributing to cost of revenue.
Confidence: medium
Not in registry
Source Natera partners for phlebotomy services and facilitates blood draws, implying significant logistics for sample transport to its labs.
Confidence: medium
Not in registryaccess=api
Source Labs require significant electricity for equipment operation, but specific share of COGS is not disclosed. Natera operates large sequencing facilities.
Confidence: low
Not in registry
Source Natera's technology is bioinformatics-based, requiring significant IT infrastructure and software, a portion of which would be directly attributable to test processing.
Confidence: low
Matchedfred · access=api · map_only
Metric/field PCEPI
Cadence monthly
Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting the addressable market for Natera's tests.
Signal to watch Increasing personal consumption expenditures on healthcare is bullish.
Confidence: high
Matchedfred · access=api · map_only
Metric/field POPTHM
Cadence monthly
Why it matters Relevant for Natera's Women's Health segment, as overall population growth, particularly of women of reproductive age, influences the addressable market for prenatal and reproductive health tests.
Signal to watch Stable or increasing total resident population growth is bullish for the women's health market.
Confidence: high
Matchedfred · access=api · map_only
Metric/field DPCERA3M086SBEA
Cadence monthly
Why it matters Disposable personal income can influence patient ability to cover out-of-pocket costs or co-pays for diagnostic tests, impacting adoption rates, especially for new or elective tests.
Signal to watch Increasing disposable personal income is bullish for consumer healthcare spending.
Confidence: high
Not in registryaccess=scrape
Metric/field Japan GDP Growth Annual
Cadence quarterly
Why it matters Natera is expanding Signatera into Japan; the overall economic health and healthcare spending capacity in Japan will influence market adoption, pricing, and reimbursement for its products.
Signal to watch Increasing annual GDP growth in Japan is bullish for market expansion and healthcare spending.
Confidence: high
Matched (medium)lab_headcount · access=api
Metric/field CES6000000001
Cadence monthly
Why it matters Growth in healthcare employment indicates overall activity and capacity within the healthcare system, which directly impacts the ordering, processing, and adoption of diagnostic tests.
Signal to watch Increasing employment in the Health Care and Social Assistance sector is bullish.
Confidence: high
Not in registry
Metric/field Overall Status, Enrollment, Primary Completion Date
Cadence event_driven
Why it matters Natera has over 70 prospective studies, including the SIGNAL program and FIND study. Monitoring their progress, enrollment, and readouts is critical for future guideline inclusions, reimbursement, and product launches.
Signal to watch Timely enrollment completion, positive status updates, and readouts for Natera-sponsored or partnered trials are bullish.
Confidence: high
Not in registry
Metric/field decision_date, product_code, device_name, applicant
Cadence daily
Why it matters FDA approvals (e.g., Signatera CDx) are major catalysts for market access, adoption, and reimbursement for Natera's diagnostic products.
Signal to watch New FDA approvals or expanded indications for Natera's products are bullish.
Confidence: high
Not in registry
Metric/field Guideline Version, Recommendation Category for ctDNA/MRD testing
Cadence irregular
Why it matters NCCN guideline inclusions, especially Category 1 recommendations, are crucial for driving physician adoption and securing broader commercial and Medicare reimbursement for Signatera.
Signal to watch New or upgraded NCCN recommendations for Signatera or tumor-informed MRD testing are bullish.
Confidence: medium
Not in registry
Metric/field Search term volume for 'Signatera test', 'Natera Panorama', 'Prospera test'
Cadence weekly
Why it matters Indicates public and physician interest and awareness in Natera's key diagnostic technologies, signaling potential market adoption and awareness.
Signal to watch Increasing search interest for Natera's key products is bullish.
Confidence: medium
Not in registry
Metric/field Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events)
Cadence event_driven
Why it matters 8-K filings often announce significant corporate events, such as regulatory approvals, clinical trial results, partnerships, or material financial updates, which can be key catalysts for Natera.
Signal to watch Filings announcing positive regulatory outcomes, strong clinical data, or new strategic partnerships are bullish.
Confidence: high
Matchediqvia_medical_claims · access=file · map_only
Metric/field CPT code utilization for Natera's molecular diagnostic tests (e.g., specific codes for Signatera, Panorama, Prospera)
Cadence monthly
Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends for Natera's products, offering insights into commercial adoption and payer coverage.
Signal to watch Increasing CPT code utilization for Natera's tests and favorable reimbursement rates are bullish.
Confidence: high
Not in registry
Metric/field Patient journeys and physician ordering patterns for MRD testing (Signatera), NIPT (Panorama), and transplant rejection monitoring (Prospera)
Cadence monthly
Why it matters Offers insights into physician adoption, referral patterns, and competitive dynamics across Natera's key therapeutic areas, particularly for Signatera's market penetration.
Signal to watch Increasing physician ordering and patient volume for Natera's tests, especially Signatera, are bullish.
Confidence: high
Matched (medium)symphony_health_medical_claims · access=file · map_only
Metric/field Prescription and claims data for related therapies and diagnostic test orders
Cadence monthly
Why it matters Provides a comprehensive view of patient care pathways, allowing for analysis of Natera's test adoption in conjunction with treatment decisions and outcomes.
Signal to watch Growing adoption of Natera's tests within relevant treatment pathways and increasing linkage to positive patient outcomes are bullish.
Confidence: high
Matchedclarivate_life_sciences_drug_intelligence · access=file · map_only
Metric/field Market size, growth rates, and competitive landscape for molecular residual disease (MRD), NIPT, and transplant diagnostics
Cadence quarterly
Why it matters Provides high-level market intelligence and forecasts for Natera's core business segments, helping to contextualize company performance within broader industry trends.
Signal to watch Upward revisions in market size and growth forecasts for Natera's key segments are bullish.
Confidence: medium
Matched (medium)norstella_market_access_formulary · access=file · map_only
Metric/field Coverage policies, reimbursement rates, and prior authorization requirements for Natera's tests (e.g., MolDx, Medicare Advantage, commercial plans)
Cadence monthly
Why it matters Directly tracks the critical reimbursement landscape for Natera, including MolDx coverage decisions and commercial payer policies, which are key drivers of ASP and revenue.
Signal to watch Favorable changes in payer coverage policies, increased reimbursement rates, and reduced prior authorization hurdles are bullish.
Confidence: high
Natera, a leader in molecular diagnostics, is poised for accelerated growth, driven by Signatera's exceptional performance, industry-first FDA/PMDA approvals, a
Natera, a leader in molecular diagnostics, is poised for accelerated growth, driven by Signatera's exceptional performance, industry-first FDA/PMDA approvals, and NCCN Category 1 recommendation. Strategic investments in a robust interventional clinical pipeline, new product launches in women's and organ health, and a significantly raised 2026 revenue outlook underpin a compelling long-term investment case, despite ongoing reimbursement and competitive dynamics. (As of 2026-10-25)
Signatera achieved industry-first US FDA approval as a companion diagnostic, Japanese PMDA approval, and a Category 1 NCCN recommendation for muscle invasive bladder cancer, validating Natera's personalized MRD technology. These regulatory and guideline achievements are driving substantial commercial adoption, new account wins, and solidifying Natera's leadership in oncology, evidenced by 56% YoY growth in clinical MRD units and a record 34,000 sequential unit increase in Q2 2026.
Natera's extensive investment in over 70 prospective clinical studies, including the new interventional SIGNAL-ER101 program for breast cancer, is entering a 'harvest phase' with accelerating readouts. This robust evidence generation, coupled with 7 MolDx submissions for Signatera, estimated to add $150-$200 to ASP over the next 12-18 months, and the pivotal FIND study for early cancer detection approaching full enrollment, creates a strong pipeline for future market expansion and significant ASP growth.
Beyond oncology, Natera demonstrates strong performance in women's health with the enhanced Panorama test driving new account wins and in organ health with expanded Medicare coverage for Prospera, effective August 30, 2026. The company's ability to maintain high gross margins (65%) while investing in new products, coupled with a clear roadmap for COGS optimization, supports sustained profitability and financial strength, with a long-term gross margin target of 70%+.
Despite recent Signatera ASP improvements to approximately $12.75, achieving the long-term $2,000 target is contingent on future MolDx coverage decisions and broader guideline inclusion, which are hard to forecast with precision. The current revenue guidance assumes stable ASPs for the rest of 2026, indicating that significant ASP uplifts from new coverages may not materialize immediately, posing a risk to near-term profitability and revenue growth.
While Natera acknowledges its strong position, the MRD market is attracting increasing competition from established players with MolDx-approved tests and new entrants. Although Natera's penetration is still in the mid-single digits, intensifying competition could lead to pricing pressures, increased commercialization costs, and potential erosion of market share, particularly as competitors also generate clinical evidence.
Natera's aggressive investment in R&D, particularly the approximately $100 million allocated to the early cancer detection (ECD) FIND study in 2026, represents a significant cash outlay that currently yields no top-line or margin benefits. While promising, the ECD market is nascent and carries inherent regulatory, clinical, and commercialization risks, and the 'growth wave' to millions of tests per year is still several years away, impacting near-term profitability.
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Completion of Enrollment for the FIND Study (Early Cancer Detection) | Full enrollment in the pivotal FIND study is a critical de-risking milestone for Natera's early cancer detection program, maintaining the timeline for a 2027 readout and positioning the company for a potentially enormous future market. | Official announcement from Natera regarding the full enrollment of approximately 24,000 average-risk adults in the FIND study, expected in Q3 2026. | Completion of enrollment in Q3 2026 is a bullish signal, indicating the program is on track for a 2027 readout and future commercialization. Delays beyond Q3 2026 would be a bearish signal. | Natera's Q3 2026 earnings conference call and press release (expected early November 2026) or dedicated company press release. | 1. ClinicalTrials.gov — Study StatusNot in registry Metric/field NCT05004387 (FIND Study) enrollment status Cadence monthly/quarterly Why it matters Provides official updates on the enrollment status of the FIND study, a key milestone for Natera's early cancer detection program. Signal to watch Status update to 'Completed' or 'Terminated' (if enrollment is complete) is bullish. Delays in status update or 'Recruiting' status beyond Q3 2026 is bearish. Confidence: High | [] |
| MolDx Coverage Decisions for 7 Submitted Signatera Indications | MolDx coverage for additional Signatera indications is a significant catalyst for long-term ASP growth, potentially adding $150-$200 to the ASP and expanding the addressable market, driving substantial revenue and margin expansion. | Announcements of MolDx Local Coverage Determinations (LCDs) for any of the 7 submitted Signatera indications over the next 12-18 months (expected rolling approvals from H2 2026 into H1 2027). | Approval of any of the 7 MolDx submissions is a bullish signal, potentially adding $150-$200 to the long-term ASP. Delays or rejections would be a bearish signal. | MolDx website (www.mol.dx.com), Natera's press releases, and SEC filings (Form 8-K, 10-Q, 10-K). | [] | 1. Advisory Board — Payer Policy DatabaseNot in registry Metric/field MolDx LCD updates for molecular diagnostic tests Cadence weekly/monthly Why it matters Monitors changes in MolDx coverage policies, directly impacting reimbursement for Natera's tests. Signal to watch New or expanded MolDx LCDs covering Signatera indications are bullish. Confidence: High |
| Signatera Average Selling Price (ASP) Sequential Increase | Improvements in Signatera's ASP are crucial for Natera's profitability and progress towards its long-term ASP target of $2,000. Tactical reimbursement wins and broader coverage directly enhance revenue per test. | Sequential increase in Signatera ASP for Q3 2026 compared to Q2 2026 (Q2 2026 ASP was approximately $12.75). Management suggested an upside case of another $25 sequential increase in the near term from tactical improvements. | A sequential ASP increase of $25 or more for Signatera is a bullish signal for near-term revenue and margin expansion. An increase below $25 would indicate slower tactical reimbursement progress. | Natera's Q3 2026 earnings conference call and press release (expected early November 2026). | [] | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field Reimbursement rates for Signatera CPT codes Cadence monthly Why it matters Provides independent data on actual reimbursement trends and ASP realization. Signal to watch Increasing reimbursement rates are bullish. Confidence: High |
| Signatera Clinical MRD Unit Sequential Growth | Sustained strong sequential growth in Signatera clinical MRD units demonstrates increasing market adoption and Natera's ability to capitalize on its leading position in the oncology diagnostics market, directly impacting revenue and future profitability. | Sequential growth in clinical MRD units for Q3 2026 compared to Q2 2026 (Q2 2026 saw 34,000 sequential units). Management expects to outperform the previous record of 25,000 units, but not necessarily the Q2 2026 record. | Sequential growth of Signatera clinical MRD units exceeding 25,000 units is a bullish signal, indicating strong momentum. Growth below 25,000 units would signal a slowdown. | Natera's Q3 2026 earnings conference call and press release (expected early November 2026). | 1. Google Trends — Search InterestNot in registry Metric/field Search term volume for 'Signatera' AND 'MRD testing' Cadence weekly Why it matters Indicates public and physician interest and awareness in Signatera and MRD testing, signaling potential market adoption. Signal to watch Sustained or increasing search interest is bullish. Confidence: Medium | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for Signatera (specific codes for ctDNA MRD testing) Cadence monthly Why it matters Provides granular, independent data on actual test utilization and market share for Signatera. Signal to watch Increasing CPT code utilization is bullish. Confidence: High |
| Commercial Launch of Signatera for Colorectal Cancer in Japan | The commercial launch of Signatera in Japan for colorectal cancer represents a significant international market expansion, leveraging prior PMDA approval and strong clinical evidence to drive new revenue streams and global market penetration. | Official announcement from Natera regarding the commercial launch of Signatera for colorectal cancer in Japan, pending final pricing and reimbursement determination, expected later this year (Q4 2026). | A successful commercial launch in Q4 2026 is a bullish signal, indicating effective execution of international expansion strategy. Delays beyond Q4 2026 would be a bearish signal. | Natera's Q3 2026 earnings conference call and press release (expected early November 2026) or dedicated company press release. | [] | 1. IQVIA / Symphony Health — Japan Pharmaceutical Market DataMatchediqvia_prescription_rx_data · access=file · map_only Metric/field Prescription/utilization data for Signatera in Japan Cadence monthly Why it matters Provides early insights into commercial adoption and sales performance of Signatera in the Japanese market. Signal to watch Increasing utilization post-launch is bullish. Confidence: Medium |
Women's Health is a core segment for Natera. Strong performance, especially overcoming seasonal softness, indicates successful product innovation and market sha
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Women's Health Revenue Growth | High-single-digit % | Women's Health is a core segment for Natera. Strong performance, especially overcoming seasonal softness, indicates successful product innovation and market share gains, contributing to diversified growth. | Women's Health revenue growth needs to accelerate to low-double-digits (10%+) year-over-year for Q3 2026, surpassing the high-single-digit growth reported in the prior period. | Strong Women's Health growth demonstrates diversified revenue streams and reduces reliance on oncology. This validates Natera's ability to innovate and capture market share in a competitive segment, contributing to overall stability and supporting a higher valuation. | |
| Total Revenue Growth (ex revenue true-ups) | 40% | This metric reflects Natera's overall top-line performance, excluding non-recurring adjustments. It indicates the underlying strength of the business across all segments and is a key indicator of financial health. | Natera needs to report total revenue (excluding true-ups) exceeding $720 million for Q3 2026, significantly beating the consensus estimate of $707.39 million and demonstrating stronger-than-expected top-line momentum towards its full-year guidance of 31% growth ex true-ups. | Beating revenue expectations signals robust underlying business strength across segments, validating Natera's market leadership and commercial execution. This reinforces the long thesis by demonstrating accelerated growth potential and improved financial health, driving a positive rerating. | |
| Signatera Clinical MRD Units Growth | 56% | Signatera is Natera's primary growth engine. Continued strong unit growth indicates increasing market adoption and leadership in oncology, directly impacting future revenue and validating commercial execution. | Signatera Clinical MRD units need to show a sequential increase of 34,000 units or more in Q3 2026, matching or exceeding the record sequential growth achieved in Q2 2026, and significantly outperforming management's expectation to beat the prior 25,000 unit record. | Exceptional sequential Signatera unit growth confirms accelerating market adoption and Natera's leadership in oncology, directly impacting future revenue and validating commercial execution. This momentum is crucial for sustaining the long-term growth thesis and driving a rerating. | |
Will Natera's Signatera clinical MRD units achieve sequential growth exceeding the previous record of 25,000 units in Q3 2026, or will growth moderate as guided
Will Natera's Signatera clinical MRD units achieve sequential growth exceeding the previous record of 25,000 units in Q3 2026, or will growth moderate as guided?
Can Natera achieve a sequential increase in Signatera's average selling price (ASP) in Q3 2026, potentially reaching the $25 upside case from tactical reimbursement improvements, or will it remain stable as guided?
Will Natera successfully complete full enrollment for its pivotal FIND study for early cancer detection in Q3 2026 as planned, maintaining the timeline for a 2027 readout and future commercialization?
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Expanding Signatera adoption and indications: Management highlighted the FDA approval of Signatera as a companion diagnostic, Japanese PMDA approval, NCCN Category 1 recommendation for bladder cancer, and new submissions, all driving commercial adoption and future growth. The SIGNAL program for interventional studies further emphasizes this focus. 2. Innovation and product development across core segments: The launch of the enhanced Panorama test in women's health, continued success of Fetal Focus and fetal RHD, ongoing R&D investments in MRD, organ health, and women's health, and significant investment in the early cancer detection (ECD) FIND study demonstrate a strong focus on maintaining a cutting-edge product portfolio. 3. Improving gross margins and average selling prices (ASPs): Management discussed efforts in revenue cycle management for Signatera, aiming for more consistent reimbursement from Medicare Advantage and commercial plans, and the potential for MolDX coverage decisions and broader guideline inclusion to drive ASPs towards a long-term target of $2,000. They also noted COGS improvements as new products scale. | Call Takeaway & ToneTakeaway: Natera reported an exceptionally strong second quarter of 2026, marked by record test volumes, robust revenue growth, and significant regulatory and clinical achievements, particularly for its Signatera oncology product. The company significantly raised its full-year revenue guidance, reflecting strong confidence in its commercial execution and product pipeline. Continued investments in R&D and clinical evidence are expected to drive future growth and margin expansion. Tone: The tone of the call was overwhelmingly positive and confident. Management expressed excitement about the company's performance, momentum, and strategic positioning, using phrases like "exceptional quarter," "on a roll," and "very strong momentum." They conveyed a clear vision for continued leadership and market expansion across their key business segments. | Prior Quarter'S Y/Y Growth By SegmentTotal Revenue: 39% year-over-year growth. Oncology (Clinical Oncology Units): 54.4% year-over-year growth. Women's Health: Specific y/y revenue growth not provided, but noted as "excellent volume performance" and "strong quarterly unit growth". Organ Health: Specific y/y revenue growth not provided, but noted as contributing to overall revenue growth. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. Sustainability and drivers of Signatera volume growth: Puneet Souda (Leerink Partners) asked for more detail on what was powering the remarkable growth and if it was sustainable. Management (Steven Chapman) attributed it to a "halo effect" from FDA approval, significant prior investments in commercial and medical affairs teams, large-scale clinical trials, cutting-edge technology, peer-reviewed evidence, and improved user experience. He acknowledged the 34k sequential growth was a "blowout record" but expected to outperform the previous record of 25k, with Q3 starting strong. 2. Signatera ASP trajectory: Daniel Brennan (TD Cowen) inquired if the recent sequential ASP increases ($25, $22) indicated a potential acceleration beyond the current guide. Management (Michael Brophy) stated the current guide assumes a stable ASP of $12.75 for the rest of the year. He suggested an upside case of another $25 in the near term from tactical improvements (Medicare Advantage compliance, biomarker state coverage). However, the larger, "transformational" impact on ASPs towards the $2,000 long-term target is expected in 2027 from MolDx indication coverage and broader guideline inclusions. 3. Impact of competition on the MRD market: David Westenberg (Piper Sandler) asked about the effect of other MRD competitors gaining traction on Natera's strong growth. Management (Steven Chapman) acknowledged competition but stated it's not a new dynamic and Natera has consistently performed well. He emphasized Natera's continued success is due to investments in technology, clinical studies, and a strong market position. He noted the market is very large, with Natera's penetration still in the "mid-single digits," implying ample room for growth despite competitors. | Revenue SegmentsTotal Revenue: approximately 38% year-over-year growth (approximately 40% year-on-year growth excluding revenue true-ups). Oncology (Clinical MRD units): approximately 56% year-over-year growth compared to Q2 of 2025. Women's Health: high-single-digit growth versus Q2 of last year on a seasonally adjusted basis. Organ Health: strong quarter, volume continued to ramp (no specific y/y percentage given). |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketSignatera became the first MRD test to get US FDA approval as a companion diagnostic and the first MRD test to get Japanese PMDA approval. The NCCN Guideline Committee issued a Category 1 recommendation for Signatera guided adjuvant treatment in muscle invasive bladder cancer. The newly enhanced Panorama test was launched, bringing the overall no call rate down to 0.5% and resulting in many new account wins. The final Medicare LCD for organ transplant surveillance (Prospera) was published, representing a meaningful expansion over the initial CMS proposal. Signatera received IVDR certification in the EU, indicated across more than 20 tumor types, streamlining future clinical trial launches and setting up for future reimbursement in Europe. A new submission to the Japanese PMDA for Signatera as a companion diagnostic in bladder cancer is underway. The SIGNAL-ER101 study, the first interventional prospective study sponsored by Natera, is open for early-stage HR positive HER2 negative breast cancer, representing a large addressable population. The pivotal FIND study for early cancer detection is approaching full enrollment, with expectations for a growth wave from 0 to millions of tests per year once launched. Submissions for 7 additional indications to MolDx are in progress, estimated to contribute $150 to $200 to the ASP. | About CompetitionNatera acknowledges persistent competition, noting that major oncology competitors have had MolDx-approved MRD tests on the market for several years. The company believes its extensive clinical evidence generation acts as a competitive moat, making it difficult for new entrants to replicate. In women's health, Natera believes it is in the best competitive position it has been in, benefiting from share gains due to recent product enhancements. Despite competition, Natera states that because the market is so large, competition does not have a significant impact on them, as they are still in the mid-single digits for overall market penetration. | About The Broader IndustryThe company believes the industry is 'crossing the sort of tipping point in the field where doctors are really starting to believe in MRD as a core part of their practice.' | Where Things Are HeadedNatera is resetting its revenue guidance to $2.85 billion to $2.91 billion, implying 31% annual growth ex true-ups. The company expects Signatera ASPs to grow substantially over time, with a long-term target of $2,000. They are comfortable about reaching 70%+ gross margin longer term, driven by major events like MolDx coverages and internal COGS projects. The pace of prospective study readouts is expected to accelerate meaningfully over the next few years, with the SIGNAL program launching multiple additional interventional studies covering significant portions of the largest tumor histologies. The FIND study for early cancer detection is on track to read out in 2027, with expectations for 'enormous future potential' and a 'growth wave from 0 currently to millions of tests per year.' MolDx indication coverage and guidelines in additional indications are expected to drive ASPs meaningfully higher in 2027. The company plans to 'keep our foot on the gas and invest in future growth.' | Updates On ThemeDiagnostics | Broader Themes EmergingAI and automation are being deployed 'across the business at a at a pretty frenetic pace' to drive efficiencies and automate workflows, allowing employees to move up the value chain. | Bullish-Leaning Quotes (Short)We had an exceptional quarter. We are clearly on a roll. This broad based acceleration is happening across tumor types. Maintaining this level of top line growth given the size of our revenue base is pretty remarkable. We are just now entering the harvest phase of an investment we began 7 years ago. We believe we are developing a genuinely differentiated product. new patients coming in for Signatera was way up. | Bearish-Leaning Quotes (Short)Q2 is typically our softest quarter for women's health due to seasonality. We do not expect to set a new volume record again in Q3. there is always going to be competition, and, you know, we have seen that I think if you if you look at you know, probably, you know, 4 years now, maybe 3+ years, there is been major oncology competitors that have had MRD tests that are approved by MolDx on the market. it is hard to forecast with precision. | HiringNatera made a significant investment in the size and breadth of its commercial team in the first half of 2025, and these new hires are now 'hitting their stride.' SG&A expenses are relatively stable in 2026 due to the successful commercial team expansion. The company is supplementing its distribution partner in Japan with direct sales and marketing efforts. AI and automation are being used to optimize workflows, allowing employees to move up the value chain in their large operations. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketSignatera became the first MRD test to receive US FDA approval as a companion diagnostic and the first MRD test to get Japanese PMDA approval. The NCCN Guideline Committee issued a Category 1 recommendation for Signatera guided adjuvant treatment in muscle invasive bladder cancer. The newly enhanced Panorama test was launched, reducing the overall no-call rate to 0.5% and resulting in many new account wins. The final Medicare LCD for organ transplant surveillance (Prospera) was published, representing a meaningful expansion over the initial CMS proposal. Signatera received IVDR certification in the EU, indicated across more than 20 tumor types, which streamlines future clinical trial launches and sets up for future reimbursement in Europe. A new submission to the Japanese PMDA for Signatera as a companion diagnostic in bladder cancer is underway. The SIGNAL-ER101 study, the first interventional prospective study sponsored by Natera, is open for early-stage HR positive HER2 negative breast cancer, representing a large addressable population. The pivotal FIND study for early cancer detection is approaching full enrollment, with expectations for a growth wave from 0 to millions of tests per year once launched. Submissions for 7 additional indications to MolDx are in progress, estimated to contribute $150 to $200 to the ASP. | About CompetitionNatera acknowledges persistent competition, noting that major oncology competitors have had MolDx-approved MRD tests on the market for several years. The company believes its extensive clinical evidence generation acts as a competitive moat, making it difficult for new entrants to replicate. In women's health, Natera believes it is in the best competitive position it has been in, benefiting from share gains due to recent product enhancements. Despite competition, Natera states that because the market is so large, competition does not have a significant impact on them, as they are still in the mid-single digits for overall market penetration. | About The Broader IndustryThe company believes the industry is 'crossing the sort of tipping point in the field where doctors are really starting to believe in MRD as a core part of their practice.' | Where Things Are HeadedNatera is resetting its revenue guidance to $2.85 billion to $2.91 billion, implying 31% annual growth excluding true-ups. The company expects Signatera ASPs to grow substantially over time, with a long-term target of $2,000. They are comfortable about reaching 70%+ gross margin longer term, driven by major events like MolDx coverages and internal COGS projects. The pace of prospective study readouts is expected to accelerate meaningfully over the next few years, with the SIGNAL program launching multiple additional interventional studies covering significant portions of the largest tumor histologies. The FIND study for early cancer detection is on track to read out in 2027, with expectations for 'enormous future potential' and a 'growth wave from 0 currently to millions of tests per year.' MolDx indication coverage and guidelines in additional indications are expected to drive ASPs meaningfully higher in 2027. The company plans to 'keep our foot on the gas and invest in future growth.' | Updates On ThemeDiagnostics | Broader Themes EmergingAI and automation are being deployed 'across the business at a at a pretty frenetic pace' to drive efficiencies and automate workflows, allowing employees to move up the value chain. | Bullish-Leaning Quotes (Short)We had an exceptional quarter. We are clearly on a roll. new patients coming in for Signatera was way up. | Bearish-Leaning Quotes (Short)Q2 is typically our softest quarter for women's health due to seasonality. We do not expect to set a new volume record again in Q3. it is hard to forecast with precision. | HiringNatera made a significant investment in the size and breadth of its commercial team in the first half of 2025, and these new hires are now hitting their stride. The successful commercial team expansion last year is contributing to SG&A being relatively stable in 2026. The company is deploying AI to automate workflows and move employees up the value chain, indicating a focus on efficiency through technology rather than just headcount expansion. |
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-08-06 | Natera reported an exceptional Q2'26 with record test volumes, 56% Signatera growth, and significant regulatory wins (FDA CDx, PMDA, NCCN Category 1). Revenue grew 38%, and full-year guidance was raised by $100M. The market reacted very positively, with the stock returning 21.37% (t+2 days), significantly outperforming SPY, reflecting strong confidence in Natera's execution and future growth prospects. | Earnings Transcript | Mixed | +21.37% (vs SPY: +20.79%) |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| NTRA_be394610 | later this year | 2026-10-01 | 2026-12-31 | Commercial launch of Signatera for colorectal cancer in Japan. | This launch is expected to drive market adoption and revenue in Japan, supported by existing society guidelines. | Ticker | 2026-08-06 | earnings_transcript |
| NTRA_c9201351 | later this year | 2026-10-01 | 2026-12-31 | Commercial launch of Signatera for colorectal cancer in Japan, pending final pricing and reimbursement determination. | This represents a significant international market expansion for Signatera, potentially driving substantial revenue growth and solidifying its global footprint in oncology diagnostics. | Ticker | 2026-08-06 | earnings_transcript |
